Sotrovimab for Injection - Risk of Treatment Failure due to Circulation of SARS-CoV-2 Omicron BA.2 Subvariant
Issued April 14, 2022
Issue
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.
Hazard description
New safety information - COVID
Product
Product name
Sotrovimab, 500 mg IV
Reference
ID
RA-64084
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker